Filing Details

Accession Number:
0001559515-20-000002
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-15 17:19:17
Reporting Period:
2020-05-13
Accepted Time:
2020-05-15 17:19:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1270073 Intercept Pharmaceuticals Inc. ICPT Pharmaceutical Preparations (2834) 223868459
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1559537 Paolo Fundaro C/O Genextra S.p.a.,
Via G. De Grassi, 11
Milan L6 20123
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.001 Per Share Disposition 2020-05-13 595,578 $84.60 5,500,000 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, Par Value $0.001 Per Share 19,433 Direct
Footnotes
  1. These shares are held by Genextra S.p.A. Mr. Fundaro is the Chief Executive Officer of Genextra S.p.A. and, in such capacity, Mr. Fundaro exercises voting control over the shares of common stock owned by Genextra S.p.A and investment control over such shares as authorized by the board of Genextra S.p.A. Mr. Fundaro disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.
  2. Genextra S.p.A. will apply the proceeds from the sale to reduce outstanding indebtedness under its margin loan secured by its shares of Intercept's common stock, and for general corporate purposes.